New aspects in the diagnosis and treatment of cushing disease

Frontiers of Hormone Research

Volumn 35, Issue , 2006, Pages 169-178

  Labeur, M ^a   Theodoropoulou, M ^a   Sievers, C ^a   Paez Pereda, M ^b   Castillo, V ^c   Arzt, E ^d   Stalla, G K ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Affectis Pharmaceutical AG   (Germany)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d INSTITUTO DE FISIOLOGÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID; SOMATOSTATIN;

ALGORITHM; ANIMAL; CONFERENCE PAPER; CUSHING DISEASE; DIFFERENTIAL DIAGNOSIS; HUMAN;

ALGORITHMS; ANIMALS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMANS; LIGANDS; PITUITARY ACTH HYPERSECRETION; PPAR GAMMA; SOMATOSTATIN; TRETINOIN;

EID: 33745791583     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000094325     Document Type: Conference Paper

References (24)

1. Arnaldi G, et al: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-5602.
2. Labeur M, et al: New perspectives in the treatment of Cushing's syndrome. Curr Drug Targets Immune Endocr Metabol Disord 2004;4:335-342.
3. Findling JW, Raff H, Aron DC: The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004;89:1222-1226.
4. Papanicolaou DA, et al: Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2002;87:4515-4521.
5. Pacak K, Eisenhofer G, Goldstein DS: Functional imaging of endocrine tumors: role of positron emission tomography. Endocr Rev 2004;25:568-580.
6. Ben-Jonathan N: Dopamine: a prolactin-inhibiting hormone. Endocr Rev 1985;6:564-589.
7. Stack J, Surprenant A: Dopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs. J Physiol 1991;439:37-58.
8. De Camilli P, Macconi D, Spada A: Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas. Nature 1979;278:252-254.
9. Colao A, Annunziato L, Lombardi G: Treatment of prolactinomas. Ann Med 1998;30:452-459.
10. Miller JW, Crapo L: The medical treatment of Cushing's syndrome. Endocr Rev 1993;14:443-458.
11. Pivonello R, et al: Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89:2452-2462.
12. Lamberts SW, Uitterlinden P, Klijn JM: The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989;120:760-766.
13. von Werder K, Muller OA, Stalla GK: Somatostatin analogs in ectopic corticotropin production. Metabolism 1996;45(suppl 1):129-131.
14. Stalla GK, et al: Octreotide exerts different effects in vivo and in vitro in Cushing's disease. Eur J Endocrinol 1994;130:125-131.
15. Holland LJ, et al: The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152:645-654.
16. Nielsen S, et al: Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo. J Endocrinol Invest 2001;24:430-437.
17. Bruns C, et al: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146:707-716.
18. Silva AP, et al: Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 2005;153:R7-R10.
19. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-954.
20. Zhang XK, et al: Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature 1992;355:441-446.
21. Paez-Pereda M, et al: Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001;108:1123-1131.
22. Heaney AP, et al: Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002;8:1281-1287.
23. Heaney AP, Fernando M, Melmed S: PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003;111:1381-1388.
24. Ambrosi B, et al: Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:173-178.